Clinical Trials Directory

Trials / Terminated

TerminatedNCT04549584

Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer

Status
Terminated
Phase
Study type
Observational
Enrollment
3 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers

Summary

prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer

Detailed description

Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement. Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response rate of the neoadjuvant chemotherapy. Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy. The group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTVimentin/pan CK stainVimentin/pan CK stain positive/negative

Timeline

Start date
2020-10-01
Primary completion
2020-12-16
Completion
2020-12-16
First posted
2020-09-16
Last updated
2020-12-17

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04549584. Inclusion in this directory is not an endorsement.